A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages S34-S44

  Baumert, Thomas F ^a,b,c   Fauvelle, Catherine ^b   Chen, Diana Y ^a   Lauer, Georg M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Antibodies.; Hepatitis C; T cells; Vaccine

Indexed keywords

HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; COHORT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; VACCINATION; ANIMAL; DISEASE MODEL; EPIDEMIC; HEPACIVIRUS; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; EPIDEMICS; HEPACIVIRUS; HEPATITIS C; HUMANS; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84913526707     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.009     Document Type: Review

References (109)

1. R.T. Chung, and T.F. Baumert Curing chronic hepatitis C - the arc of a medical triumph N Engl J Med 370 2014 1576 1578
2. A.L. Cox, and D.L. Thomas Hepatitis C virus vaccines among people who inject drugs Clin Infect Dis 57 2013 S46 S50
3. E. Callaway Hepatitis C drugs not reaching Nature 508 2014 295 296
4. T.J. Liang, and M.G. Ghany Therapy of hepatitis C - back to the future N Engl J Med 370 2014 2043 2047
5. A.Y. Kim, S. Onofrey, and D.R. Church An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection J Infect Dis 207 2013 S1 S6
6. N.K. Martin, M. Hickman, S.J. Hutchinson, D.J. Goldberg, and P. Vickerman Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy Clin Infect Dis 57 2013 S39 S45
7. R. Verma, P. Khanna, and S. Chawla Hepatitis C vaccine: need of the hour Hum Vaccines Immunotherapeutics 10 8 2014 [Epub ahead of print]
8. M.D. Krahn, A. John-Baptiste, Q. Yi, A. Doria, R.S. Remis, and P. Ritvo Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada Vaccine 23 2005 1549 1558
9. J.A. Hahn, D. Wylie, J. Dill, M.S. Sanchez, J.O. Lloyd-Smith, and K. Page-Shafer Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users Epidemics 1 2009 47 57
10. G.M. Lauer, and B.D. Walker Hepatitis C virus infection N Engl J Med 345 2001 41 52
11. S.H. Mehta, A. Cox, D.R. Hoover, X.H. Wang, Q. Mao, and S. Ray Protection against persistence of hepatitis C Lancet 359 2002 1478 1483
12. S. Raghuraman, H. Park, W.O. Osburn, E. Winkelstein, B.R. Edlin, and B. Rehermann Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion J Infect Dis 205 2012 763 771
13. P. Simmonds Genetic diversity and evolution of hepatitis C virus - 15 years on J Gen Virol 85 2004 3173 3188
14. R. Thimme, J. Bukh, H.C. Spangenberg, S. Wieland, J. Pemberton, and C. Steiger Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease Proc Natl Acad Sci USA 99 2002 15661 15668
15. R. Thimme, D. Oldach, K.M. Chang, C. Steiger, S.C. Ray, and F.V. Chisari Determinants of viral clearance and persistence during acute hepatitis C virus infection J Exp Med 194 2001 1395 1406
16. H.M. Diepolder, R. Zachoval, R.M. Hoffmann, M.C. Jung, T. Gerlach, and G.R. Pape The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C J Mol Med (Berl) 74 1996 583 588
17. F. Lechner, D.K. Wong, P.R. Dunbar, R. Chapman, R.T. Chung, and P. Dohrenwend Analysis of successful immune responses in persons infected with hepatitis C virus J Exp Med 191 2000 1499 1512
18. N.H. Shoukry, A. Grakoui, M. Houghton, D.Y. Chien, J. Ghrayeb, and K.A. Reimann Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection J Exp Med 197 2003 1645 1655
19. D.G. Bowen, and C.M. Walker Adaptive immune responses in acute and chronic hepatitis C virus infection Nature 436 2005 946 952
20. J.T. Gerlach, H.M. Diepolder, M.C. Jung, N.H. Gruener, W.W. Schraut, and R. Zachoval Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C Gastroenterology 117 1999 933 941
21. D.E. Kaplan, K. Sugimoto, K. Newton, M.E. Valiga, F. Ikeda, and A. Aytaman Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C Gastroenterology 132 2007 654 666
22. A.L. Cox, T. Mosbruger, G.M. Lauer, D. Pardoll, D.L. Thomas, and S.C. Ray Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C Hepatology 42 2005 104 112
23. C.M. Walker Adaptive immunity to the hepatitis C virus Adv Virus Res 78 2010 43 86
24. B. Rehermann Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 2009 1745 1754
25. S. Cooper, A.L. Erickson, E.J. Adams, J. Kansopon, A.J. Weiner, and D.Y. Chien Analysis of a successful immune response against hepatitis C virus Immunity 10 1999 439 449
26. A. Grakoui, N.H. Shoukry, D.J. Woollard, J.H. Han, H.L. Hanson, and J. Ghrayeb HCV persistence and immune evasion in the absence of memory T cell help Science 302 2003 659 662
27. N.H. Gruner, T.J. Gerlach, M.C. Jung, H.M. Diepolder, C.A. Schirren, and W.W. Schraut Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C J Infect Dis 181 2000 1528 1536
28. S. Urbani, B. Amadei, P. Fisicaro, D. Tola, A. Orlandini, and L. Sacchelli Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses Hepatology 44 2006 126 139
29. K. Fitzmaurice, D. Petrovic, N. Ramamurthy, R. Simmons, S. Merani, and S. Gaudieri Molecular footprints reveal the impact of the protective HLA-A∗03 allele in hepatitis C virus infection Gut 60 2011 1563 1571
30. E. Dazert, C. Neumann-Haefelin, S. Bressanelli, K. Fitzmaurice, J. Kort, and J. Timm Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response J Clin Invest 119 2009 376 386
31. M.H. Kuniholm, A. Kovacs, X. Gao, X. Xue, D. Marti, and C.L. Thio Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia Hepatology 51 2010 1514 1522
32. B. Bengsch, R. Thimme, and H.E. Blum Role of host genetic factors in the outcome of hepatitis C virus infection Viruses 1 2009 104 125
33. A.Y. Kim, T. Kuntzen, J. Timm, B.E. Nolan, M.A. Baca, and L.L. Reyor Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes Gastroenterology 140 2011 686 696 e681
34. P. Duggal, C.L. Thio, G.L. Wojcik, J.J. Goedert, A. Mangia, and R. Latanich Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts Ann Intern Med 158 2013 235 245
35. C. Neumann-Haefelin, and R. Thimme Success and failure of virus-specific T cell responses in hepatitis C virus infection Dig Dis 29 2011 416 422
36. P. Klenerman, and R. Thimme T cell responses in hepatitis C: the good, the bad and the unconventional Gut 61 2012 1226 1234
37. R. Thimme, J. Bukh, H.C. Spangenberg, S. Wieland, J. Pemberton, and C. Steiger Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease Proc Natl Acad Sci USA 99 2002 15661 15668
38. J.T. Gerlach, H.M. Diepolder, M.C. Jung, N.H. Gruener, W.W. Schraut, and R. Zachoval Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C Gastroenterology 117 1999 933 941
39. J. Schulze zur Wiesch, G.M. Lauer, C.L. Day, A.Y. Kim, K. Ouchi, and J.E. Duncan Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes J Immunol 175 2005 3603 3613
40. C.L. Day, G.M. Lauer, G.K. Robbins, B. McGovern, A.G. Wurcel, and R.T. Gandhi Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection J Virol 76 2002 12584 12595
41. K. Sugimoto, F. Ikeda, J. Stadanlick, F.A. Nunes, H.J. Alter, and K.M. Chang Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection Hepatology 38 2003 1437 1448
42. J. Schulze Zur Wiesch, D. Ciuffreda, L. Lewis-Ximenez, V. Kasprowicz, B.E. Nolan, and H. Streeck Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence J. Exp. Med. 209 2012 61 75
43. J. Zhu, and W.E. Paul CD4 T cells: fates, functions, and faults Blood 112 2008 1557 1569
44. H. Kared, T. Fabre, N. Bedard, J. Bruneau, and N.H. Shoukry Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C PLoS Pathog 9 2013 e1003422
45. A.G. Rowan, J.M. Fletcher, E.J. Ryan, B. Moran, J.E. Hegarty, and C. O'Farrelly Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta J Immunol 181 2008 4485 4494
46. M.T. Brady, A.J. MacDonald, A.G. Rowan, and K.H. Mills Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes Eur J Immunol 33 2003 3448 3457
47. J. Timm, G.M. Lauer, D.G. Kavanagh, I. Sheridan, A.Y. Kim, and M. Lucas CD8 epitope escape and reversion in acute HCV infection J Exp Med 200 2004 1593 1604
48. A.L. Cox, T. Mosbruger, Q. Mao, Z. Liu, X.H. Wang, and H.C. Yang Cellular immune selection with hepatitis C virus persistence in humans J Exp Med 201 2005 1741 1752
49. A.L. Erickson, Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, and J. Sidney The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes Immunity 15 2001 883 895
50. T. Kuntzen, J. Timm, A. Berical, L.L. Lewis-Ximenez, A. Jones, and B. Nolan Viral sequence evolution in acute hepatitis C virus infection J Virol 81 2007 11658 11668
51. C. Neumann-Haefelin, D.N. Frick, J.J. Wang, O.G. Pybus, S. Salloum, and G.S. Narula Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level J Virol 82 2008 3438 3451
52. C. Neumann-Haefelin, C. Oniangue-Ndza, T. Kuntzen, J. Schmidt, K. Nitschke, and J. Sidney Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations Hepatology 54 2011 1157 1166
53. A.Y. Kim, T. Kuntzen, J. Timm, B.E. Nolan, M.A. Baca, and L.L. Reyor Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes Gastroenterology 140 2011 e681
54. C. Neumann-Haefelin, S. McKiernan, S. Ward, S. Viazov, H.C. Spangenberg, and T. Killinger Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution Hepatology 43 2006 563 572
55. C. Neumann-Haefelin, C. Oniangue-Ndza, T. Kuntzen, J. Schmidt, K. Nitschke, and J. Sidney Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations Hepatology 54 2011 1157 1166
56. C. Oniangue-Ndza, T. Kuntzen, M. Kemper, A. Berical, Y.E. Wang, and C. Neumann-Haefelin Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase J Virol 85 2011 11883 11890
57. J.M. Angelosanto, S.D. Blackburn, A. Crawford, and E.J. Wherry Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection J Virol 86 2012 8161 8170
58. E.J. Wherry T cell exhaustion Nat Immunol 12 2011 492 499
59. S.D. Blackburn, H. Shin, W.N. Haining, T. Zou, C.J. Workman, and A. Polley Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 10 2009 29 37
60. D.L. Barber, E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, and A.H. Sharpe Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 2006 682 687
61. V. Kasprowicz, J. Schulze Zur Wiesch, T. Kuntzen, B.E. Nolan, S. Longworth, and A. Berical High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection irrespective of clinical outcome J Virol 82 2008 3154 3160
62. K. Blom, M. Braun, M.A. Ivarsson, V.D. Gonzalez, K. Falconer, and M. Moll Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response J Immunol 190 2013 2150 2158
63. A. Rutebemberwa, S.C. Ray, J. Astemborski, J. Levine, L. Liu, and K.A. Dowd High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection J Immunol 181 2008 8215 8225
64. R. Cabrera, Z. Tu, Y. Xu, R.J. Firpi, H.R. Rosen, and C. Liu An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection Hepatology 40 2004 1062 1071
65. D. Accapezzato, V. Francavilla, M. Paroli, M. Casciaro, L.V. Chircu, and A. Cividini Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection J Clin Invest 113 2004 963 972
66. S. Smyk-Pearson, L. Golden-Mason, J. Klarquist, J.R. Burton Jr., I.A. Tester, and C.C. Wang Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection J Infect Dis 197 2008 46 57
67. T. Boettler, H.C. Spangenberg, C. Neumann-Haefelin, E. Panther, S. Urbani, and C. Ferrari T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection J Virol 79 2005 7860 7867
68. S.M. Rushbrook, S.M. Ward, E. Unitt, S.L. Vowler, M. Lucas, and P. Klenerman Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection J Virol 79 2005 7852 7859
69. A.P. West Jr., L. Scharf, J.F. Scheid, F. Klein, P.J. Bjorkman, and M.C. Nussenzweig Structural insights on the role of antibodies in HIV-1 vaccine and therapy Cell 156 2014 633 648
70. G.J. Nabel Designing tomorrow's vaccines N Engl J Med 368 2013 551 560
71. N. Semmo, M. Lucas, G. Krashias, G. Lauer, H. Chapel, and P. Klenerman Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy Blood 107 2006 4570 4571
72. J.M. Pestka, M.B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch, and F.L. Cosset Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C Proc Natl Acad Sci USA 104 2007 6025 6030
73. W.O. Osburn, A.E. Snider, B.L. Wells, R. Latanich, J.R. Bailey, and D.L. Thomas Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses Hepatology 59 6 2014 2140 2151
74. W.O. Osburn, B.E. Fisher, K.A. Dowd, G. Urban, L. Liu, and S.C. Ray Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection Gastroenterology 138 2010 315 324
75. C. Feray, M. Gigou, D. Samuel, B. Ducot, P. Maisonneuve, and M. Reynes Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation Ann Intern Med 128 1998 810 816
76. S. Fafi-Kremer, I. Fofana, E. Soulier, P. Carolla, P. Meuleman, and G. Leroux-Roels Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation J Exp Med 207 2010 2019 2031
77. I. Fofana, S. Fafi-Kremer, P. Carolla, C. Fauvelle, M.N. Zahid, and M. Turek Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies Gastroenterology 143 2012 223 233 e229
78. T. von Hahn, J.C. Yoon, H. Alter, C.M. Rice, B. Rehermann, and P. Balfe Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo Gastroenterology 132 2007 667 678
79. M. Gal-Tanamy, Z.Y. Keck, M. Yi, J.A. McKeating, A.H. Patel, and S.K. Foung In vitro selection of a neutralization-resistant hepatitis C virus escape mutant Proc Natl Acad Sci USA 105 2008 19450 19455
80. F. Helle, G. Vieyres, L. Elkrief, C.I. Popescu, C. Wychowski, and V. Descamps Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions J Virol 84 2010 11905 11915
81. J.M. Timpe, Z. Stamataki, A. Jennings, K. Hu, M.J. Farquhar, and H.J. Harris Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies Hepatology 47 2008 17 24
82. C.L. Brimacombe, J. Grove, L.W. Meredith, K. Hu, A.J. Syder, and M.V. Flores Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission J Virol 85 2011 596 605
83. J. Grove, S. Nielsen, J. Zhong, M.F. Bassendine, H.E. Drummer, and P. Balfe Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies J Virol 82 2008 12020 12029
84. P. Andre, F. Komurian-Pradel, S. Deforges, M. Perret, J.L. Berland, and M. Sodoyer Characterization of low- and very-low-density hepatitis C virus RNA-containing particles J Virol 76 2002 6919 6928
85. P. Zhang, L. Zhong, E.B. Struble, H. Watanabe, A. Kachko, and K. Mihalik Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity Proc Natl Acad Sci USA 106 2009 7537 7541
86. Z. Keck, W. Wang, Y. Wang, P. Lau, T.H. Carlsen, and J. Prentoe Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein J Virol 87 2013 37 51
87. A.W. Tarr, A.M. Owsianka, J.M. Timms, C.P. McClure, R.J. Brown, and T.P. Hickling Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 Hepatology 43 2006 592 601
88. Z.Y. Keck, T.K. Li, J. Xia, M. Gal-Tanamy, O. Olson, and S.H. Li Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies J Virol 82 2008 6061 6066
89. M. Law, T. Maruyama, J. Lewis, E. Giang, A.W. Tarr, and Z. Stamataki Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge Nat Med 14 2008 25 27
90. L. Kong, E. Giang, T. Nieusma, R.U. Kadam, K.E. Cogburn, and Y. Hua Hepatitis C virus E2 envelope glycoprotein core structure Science 342 2013 1090 1094
91. A.G. Khan, J. Whidby, M.T. Miller, H. Scarborough, A.V. Zatorski, and A. Cygan Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2 Nature 509 7500 2014 381 384
92. A. Folgori, S. Capone, L. Ruggeri, A. Meola, E. Sporeno, and B.B. Ercole A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees Nat Med 12 2006 190 197
93. E. Barnes, A. Folgori, S. Capone, L. Swadling, S. Aston, and A. Kurioka Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man Sci Transl Med 4 2012 115ra111
94. A. Fournillier, L. Frelin, E. Jacquier, G. Ahlen, A. Brass, and E. Gerossier A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus J Infect Dis 208 2013 1008 1019
95. Q.L. Choo, G. Kuo, R. Ralston, A. Weiner, D. Chien, and G. Van Nest Vaccination of chimpanzees against infection by the hepatitis C virus Proc Natl Acad Sci USA 91 1994 1294 1298
96. J.C. Meunier, J.M. Gottwein, M. Houghton, R.S. Russell, S.U. Emerson, and J. Bukh Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus J Infect Dis 204 2011 1186 1190
97. S.E. Frey, M. Houghton, S. Coates, S. Abrignani, D. Chien, and D. Rosa Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults Vaccine 28 2010 6367 6373
98. Z. Stamataki, S. Coates, S. Abrignani, M. Houghton, and J.A. McKeating Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains J Infect Dis 204 2011 811 813
99. D. Drane, E. Maraskovsky, R. Gibson, S. Mitchell, M. Barnden, and A. Moskwa Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers Hum Vaccines 5 2009 151 157
100. P. Garrone, A.C. Fluckiger, P.E. Mangeot, E. Gauthier, P. Dupeyrot-Lacas, and J. Mancip A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques Sci Transl Med 3 94 2011 94ra71
101. G.A. Elmowalid, M. Qiao, S.H. Jeong, B.B. Borg, T.F. Baumert, and R.K. Sapp Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees Proc Natl Acad Sci USA 104 2007 8427 8432
102. E. Beaumont, R. Patient, C. Hourioux, I. Dimier-Poisson, and P. Roingeard Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine Hepatology 57 2013 1303 1313
103. D. Akazawa, M. Moriyama, H. Yokokawa, N. Omi, N. Watanabe, and T. Date Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice Gastroenterology 145 2013 447 455 e441-444
104. C. Kelly, A. Folgori, S. Capone, A.C. Brown, L. Swadling, and R. Townsend In vivo antigenic targets of t cells induced by adenoviral vectored vaccines in patients with chronic HCV infection J Hepatol 56 2012 S468-S468
105. C. Firbas, B. Jilma, E. Tauber, V. Buerger, S. Jelovcan, and K. Lingnau Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects Vaccine 24 2006 4343 4353
106. C.S. Klade, H. Wedemeyer, T. Berg, H. Hinrichsen, G. Cholewinska, and S. Zeuzem Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastroenterology 134 2008 1385 1395
107. V. Schlaphoff, C.S. Klade, B. Jilma, S.B. Jelovcan, M. Cornberg, and E. Tauber Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients Vaccine 25 2007 6793 6806
108. C.S. Klade, E. Schuller, T. Boehm, A. von Gabain, and M.P. Manns Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination Vaccine 30 2012 2943 2950
109. F. Habersetzer, G. Honnet, C. Bain, M. Maynard-Muet, V. Leroy, and J.P. Zarski A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C Gastroenterology 141 2011 890 899 e891-894